RAPT Therapeutics and Shanghai Jeyou Pharmaceutical Announce Positive Topline Data from Phase 2 Trial of RPT904 (JYB1904) in Chronic Spontaneous Urticaria

Stock Information for RAPT Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About RAPT Therapeutics Inc.

RAPT Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
RAPT Therapeutics Initiates prestIgE Phase 2b Clinical Trial of Ozureprubart (RPT904) in Patients with Food Allergies
RAPT Therapeutics Announces Pricing of Public Offering of Common Stock
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
RAPT Therapeutics Announces FDA Clearance of IND Application to Proceed to Phase 2b Trial of RPT904 in Food Allergy
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.